Cellectis (CLLS) Surges as Analyst Says Competitor Collaboration Confirms Move to CLLS-Like Allogeneic CAR-T
Tweet Send to a Friend
Cellectis (NASDAQ: CLLS) is adding to recent gains (+18.9%) after Oppenheimer analyst Christopher Marai, who recently launched bullish coverage on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
